Merck (MSD outside North America) has signed an exclusive licence and partnership agreement with Kelun-Biotech for developing seven investigational preclinical antibody-drug conjugates (ADC) to treat cancer.

As per the deal, Merck will receive exclusive international licences from Kelun-Biotech for carrying out the research, development, production and marketing of these ADC therapies.

Additionally, Merck will obtain exclusive options for further licences to ADC candidates. 

The right for conducting the research, development, production and marketing of specific licenced and option ADCs in mainland China, Hong Kong and Macau will be retained by Kelun-Biotech.

Under the agreement, Merck will make $175m in upfront payment to Kelun-Biotech.

Kelun-Biotech is entitled to get payments of up to $9.3bn in the future on meeting development, regulatory and sales milestones.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This payment is contingent on Kelun-Biotech not retaining mainland China, Macau and Hong Kong rights for the option ADCs and all candidates obtaining regulatory approval.

Merck will also make tiered royalty payments on net sales for any ADC product commercialised to Kelun-Biotech. 

Furthermore, Kelun-Biotech is eligible to get equity investment from Merck. 

Merck Research Laboratories president Dr Dean Li said: “Advances in ADC technologies are yielding a new generation of candidates designed to more precisely target and deliver potent anticancer agents to the tumour site. 

“We continue to augment our oncology pipeline and look forward to working with the Kelun-Biotech team to advance these candidates to the patients that need them.”

The latest development comes after the company entered a definitive agreement to acquire all outstanding shares of Imago BioSciences, through a subsidiary, in a deal totalling nearly $1.35bn.